We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Outlines How Exploratory IND Sponsors Can Speed Development
FDA Outlines How Exploratory IND Sponsors Can Speed Development
April 13, 2005
Sponsors of exploratory clinical trials involving drugs and therapeutic biological products have not been taking full advantage of the flexibility offered in terms of the amount of data that needs to be submitted with early exploratory investigational new drug (IND) applications, according to the FDA.